TxCell hires Lentigen to make vectors used to produce its organ rejection cell therapy

By Gareth Macdonald contact

- Last updated on GMT

TxCell SA has hired Lentigen Technology Inc. to make the vectors it uses to make its T-cell transplant rejection therapy.

The deal – financial terms of which were not disclosed – Lentigen make HLA‑A2 CAR lentiviral vector for the production of CAR-Treg transplantation (ENTX#SOT), a cell therapy TxCell is developing with the University of British Columbia.

ENTX#SOT is designed to prevent graft-versus-host disease after transplantation. It was developed using TxCell’s ENTrIA platform which uses chimeric antigen receptors (CARs) to direct antigen-specific regulatory cells (Ag-Tregs) to target autoimmune diseases.

The cell therapy is due to enter first-in-man studies at the end of next year​.

Lentigen – which is owned by Miltenyi Biotec GmbH​ – will make HLA-A2 CAR lentiviral vectors batches for the trials. It will also make vectors for planned preclinical studies.

TxCell is looking for a second contract manufacturing organisation (CMO) to use the vectors to produce ENTX#SOT.

The French biotechnology firm said it is developing a manufacturing process for CAR‑Treg cells and expects to start the technology transfer to the selected CMO by the end of the year.

TxCell has previously announced deals with Belgian CMO MaSTherCell​ and US contractor PCT​, a subsidiary of Caladrius Biosciences, both of which focused on the manufacture of its – which made the T-cell Crohn’s disease therapy, Ovasave.

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more